Biopharmaceutical company ThromboGenics announced it intended to change its name to Oxurion NV to better reflect its activities and ambition to deliver eye disorder therapies.
Biopharmaceutical company TiGenix reported that the conditions for the €1.78 per share takeover bid by Japanese pharmaceutical company Takeda had been met with acceptance by 90.62% of security holders.
Mithra Pharmaceuticals announced it had €77.5 million in gross proceeds by a private placement of 2,672,414 new shares through an accelerated bookbuild offer.
Biotechnology drug company Galapagos reported revenue for the first quarter of 2018 was up at €44.8 million from €39.9 million in the same period of 2017.
Biopharmaceutical company UCB reported revenue in the first quarter of 2018 was slightly lower at €1.07 billion but flat adjusted for the allergy drug divestiture in 2017.
Molecular diagnostics company MDxHealth reported total global patient test volumes rose in the first quarter of 2018 by 55% to 9,300 from 6,000 in the same period of 2017.
Health technology company Philips reported sales of €3.9 billion for the first quarter of 2018 with comparable sales growth of 5%.
Healthcare supplier Fagron reported it had organic growth of 6.8% in the first quarter of 2018 with turnover of €109.1 million.
Biotechnology company Argenx announced it had appointed Mr R. Keith Woods as Chief Operating Officer.
Biopharmaceutical company UCB announced it had acquired Element Genomics, a small size biotech spinoff from Duke University, based in North Carolina, USA.
Healthcare supplier Fagron announced it had acquired US based Humco, a developer, manufacturer and supplier of patented delivery vehicles and branded pharmaceutical products.
Biopharmaceutical company Ablynx announced the €3.9 billion public offer by Sanofi for all of its outstanding shares will commence 4 April 2018.
Biopharmaceutical company ThromboGenics reported it generated income of €9.1 million in 2017 compared to €7.1 million in 2016 and had advanced its pipeline of novel drug candidates for the treatment of diabetic eye disease.
Biotechnology company Pharming Group reported revenue in 2017 jumped to €89.6 million from €15.9 million in 2016 and it had its first year of operational profitability.
Women's health specialist Mithra Pharmaceuticals reported revenue more than doubled in 2017 to €46.3 million from €22.5 million in 2016 primarily due to licensing revenues from recent partnership agreements.
Biotechnology company Argenx reported income was up in 2017 at €41.3 million from €17.2 million in 2016 with progress made in its pipeline of antibody-based therapies.
Biotechnology drug company Galapagos reported revenue increased in 2017 to €155.9 million compared to €151.6 million in 2016.
Biopharmaceutical company UCB reported revenue was up 9% in 2017 at €4,530 million from €4,147 million in 2016 driven by core product sales growth of 13%.
Biopharmaceutical company Ablynx reported revenue was lower in 2017 at €55.5 million compared to €85.2 million in 2016 due to lower upfront and grant payments.
Molecular diagnostics company MDxHealth reported product revenue in 2017 increased by 13% to US$28.2 million and total revenue increased by 35% to US$40.5 million with continued strong volume growth.
Biopharmaceutical company Ablynx announced Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting, has resigned from the Board of Directors with immediate effect for personal reasons.
Healthcare supplier Fagron reported turnover increased in 2017 by 3.6% to €436.9 million compared to €421.8 million in 2016.
Health technology company Philips reported sales in 2016 increased by 4% to €17,780 million from €17,422 million in 2016.
Biopharmaceutical company Ablynx announced it was appointing Robert Friesen, PhD, as Chief Scientific Officer effective 1 March 2018.
Health technology company Philips announced that Vitor Rocha, who previously led Philips’ global Ultrasound business, has succeeded Brent Shafer as CEO of Philips North America.
Biopharmaceutical company Ablynx reported that it had rejected a takeover offer from Novo Nordisk on 22 December 2017 to acquire all of Ablynx's shares for €28.00 per share with two potential extra cash payments of up to €2.50 per share.
Biopharmaceutical company Ablynx announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board, with immediate effect, and will be succeeded by Dr Bo Jesper Hansen who has been a Non-executive Director of Ablynx since November 2013.
Biopharmaceutical company TiGenix confirmed that Takeda Pharmaceutical Company intended to launch a cash takeover bid for TiGenix at a price of €1.78 per share.
Biotechnology company Argenx announced it had commenced an underwritten US public offering of $150 million of its American Depositary Shares.
Health technology company Philips announced it had acquired Dutch based software company Forcare to expand its clinical informatics portfolio.